Table A2.
Summary of 2-Year OS, DFS, and Frequency of Locoregional Recurrence and Distant Metastasis According to Clinical and Pathologic Response
| Characteristic | Experimental Arm (%) |
Control Arm (%)Surgery Plus Radiotherapy (n = 128) | |||
|---|---|---|---|---|---|
| CR or PR (n = 100) | SD or PD (n = 22) | Pathologic Response |
|||
| Favorable (n = 33) | Unfavorable (n = 86) | ||||
| OS | 72.5 | 52.4 | 89.9 | 61.8 | 68.2 |
| DFS | 67.9 | 40.1 | 87.6 | 54.0 | 63.6 |
| Locoregional recurrence–free survival | 67.9 | 40.1 | 87.8 | 53.8 | 65.4 |
| Distant metastasis–free survival | 70.9 | 53.1 | 87.3 | 60.9 | 65.4 |
| Locoregional recurrence rate | 26.0 | 59.1 | 15.2 | 37.2 | 30.5 |
| Distant metastasis rate | 6.0 | 4.5 | 6.9 | 5.8 | 8.6 |
Abbreviations: CR, complete response; DFS, disease-free survival; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease.